Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]Ac-DOTATATE in GEP-NENs
NCT06732505Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of actinium-225 dotatate in Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety and tolerability of 225Ac-DOTATATE at 32 weeks and Recommended phase II dose of 225Ac-DOTATATE at 56 days. Started Sep 2024; status: recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN)
Beyond the preview
Go deeper on NCT06732505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732505.